The use of aromatase inhibitors in adjuvant therapy for early breast cancer

2005 ◽  
Vol 56 (S1) ◽  
pp. 32-38 ◽  
Author(s):  
Walter Jonat ◽  
Felix Hilpert ◽  
Nicolai Maass
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

2006 ◽  
Vol 24 (16) ◽  
pp. 2444-2447 ◽  
Author(s):  
Ian E. Smith ◽  
Mitch Dowsett ◽  
Yoon-Sim Yap ◽  
Geraldine Walsh ◽  
Per E. Lønning ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Ovarian Function ◽  
Younger Women ◽  
Hormone Receptor Positive ◽  
Highly Sensitive ◽  
Positive Breast Cancer

Purpose Aromatase inhibitors (AIs) are now established as adjuvant therapy for early hormone receptor–positive breast cancer in postmenopausal women. Their use is sometimes extended to younger women after chemotherapy-induced amenorrhoea; we have audited this in one institution's breast unit, and we propose guidelines for use in such circumstances. Patients and Methods The use of aromatase inhibitors as adjuvant therapy in younger women age ≥ 40 with hormone receptor–positive early breast cancer and chemotherapy-induced amenorrhea has been audited clinically and biochemically. Results A total of 45 such women were identified in the audit, with a median age of 47 years (range, 39 to 52 years). Twelve women (27%) showed a return of ovarian function (10 renewed menses, one pregnancy, one biochemically premenopausal) after starting an AI. Median age at restart of ovarian function was 44 years (range, 40 to 50 years). Conclusion AIs may promote recovery of ovarian function in some women with chemotherapy-induced amenorrhea and should be used with caution. Biochemical monitoring of ovarian function requires highly sensitive immunoassays. Guidelines for the selection and delivery of adjuvant endocrine therapy in such patients are proposed.

scholarly journals The role of aromatase inhibitors as adjuvant therapy in early breast cancer

2004 ◽  
Vol 7 (10) ◽  
Author(s):  
A. U. Buzdar
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Early Stage ◽  
Clinical Status ◽  
Hormone Receptor Positive ◽  
Breast Cancer Study ◽  
Adjuvant Breast Cancer

Endocrine therapy is now established as the treatment option of choice for postmenopausal women with hormone receptor-positive advanced breast cancer. The benefit of the third-generation aromatase inhibitors (AIs) in this setting has prompted their evaluation in the treatment of early breast cancer. This article reviews the current clinical status of AIs as adjuvant therapy for early-stage breast cancer in postmenopausal women, focusing on the largest adjuvant breast cancer study till date to provide data, the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial.

scholarly journals Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis

2017 ◽  
Vol 110 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Hadar Goldvaser ◽  
Tristan A Barnes ◽  
Boštjan Šeruga ◽  
David W Cescon ◽  
Alberto Ocaña ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Meta Analysis ◽  
Extended Adjuvant Therapy
Sign in / Sign up

Export Citation Format

Share Document